Pyxis Oncology Inc
PYXS
NASDAQ
Biotechnology
$3.01
USD
0.00 (0.00%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $190.70M
Volume 701.1K
Revenue
$11.04M
TTM
+291.4%
YoY
Gross Margin
78%
TTM
-21.6%
YoY
Net Income
$-88.73M
TTM
+7.9%
YoY
Operating Cash Flow
$-67.91M
TTM
+7.9%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 2.8 | 0.0 | 11.0 | 0.0 | 0.0 |
YoY Growth | — | — | — | — | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 2.4 | 0.0 | 0.0 |
Gross Profit | 2.8 | 0.0 | 8.7 | 0.0 | 0.0 |
Selling, General & Administrative | 5.4 | 5.7 | 5.2 | 4.4 | 9.9 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 22.6 | 23.5 | 26.9 | 24.4 | 26.0 |
Operating Income | -19.8 | -23.5 | -18.3 | -24.4 | -26.0 |
EBITDA | -19.2 | -22.9 | -15.4 | -23.9 | -25.7 |
Other Income / Expense | 0.7 | 0.7 | 0.7 | 0.6 | 0.4 |
Total Other Income / Expense | 1.7 | 1.5 | 1.3 | 1.1 | 0.6 |
Income Before Income Taxes | -18.1 | -22.0 | -17.0 | -23.3 | -25.3 |
Income Taxes | 0.3 | 0.0 | 1.1 | 0.0 | 0.0 |
Net Income | -18.4 | -22.0 | -18.1 | -23.3 | -25.3 |
Consolidated Net Income / Loss | -18.4 | -22.0 | -18.1 | -23.3 | -25.3 |
Net Income Attributable to Common Shareholders | -18.4 | -22.0 | -18.1 | -23.3 | -25.3 |
Basic EPS | -$0.30 | -$0.35 | -$0.29 | -$0.37 | -$0.40 |
Diluted EPS | -$0.30 | -$0.35 | -$0.29 | -$0.37 | -$0.40 |
Basic Shares Outstanding | 61.9M | 62.6M | 63.0M | 63.5M | 64.0M |
Diluted Shares Outstanding | 61.9M | 62.6M | 63.0M | 63.5M | 64.0M |